Accueil>>Signaling Pathways>> Others>>ERDRP-0519

ERDRP-0519

Catalog No.GC64107

ERDRP-0519, un inhibiteur de la polymérase du virus de la rougeole (MeV) À petite molécule biodisponible par voie orale, prévient la maladie de la rougeole chez les singes écureuils (Saimiri sciureus).

Products are for research use only. Not for human use. We do not sell to patients.

ERDRP-0519 Chemical Structure

Cas No.: 1374006-96-8

Taille Prix Stock Qté
5 mg
378,00 $US
En stock
10 mg
531,00 $US
En stock
25 mg
945,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ERDRP-0519, an orally bioavailable small-molecule Measles virus (MeV) polymerase inhibitor, prevents measles disease in squirrel monkeys (Saimiri sciureus). ERDRP-0519 inhibits morbilliviruses with nanomolar potency.[1][2][3].

ERDRP-0519 exhibits potency against a panel of Measles virus (MeV) isolates with EC50s of 0.07- 0.3 µM[1]. ERDRP-0519 exhibits potency against MeV and related pathogens of the Morbillivirus genus, such as canine distemper virus (CDV)[3].

A single-dose pharmacokinetic (PK) study is performed in squirrel monkeys by oral (intragastric) delivery of ERDRP-0519 (50 mg/kg) and blood sampling at seven predefined time points after dosing. Serum concentrations peak ~2 h post-administration (Cmax=3.27 µM)[3].

[1]. Wittwer K, et al. Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding. Nat Commun. 2021 Sep 2;12(1):5233.

Avis

Review for ERDRP-0519

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ERDRP-0519

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.